COMP <GO>
GSK vs UNH // ALTMAN Z-SCORE & DEBT/EQUITY
GSK plc American (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: GSK 7
— UNH 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: GSK
LAST: $49.51 (+1.71%) • MKT CAP: $98.47B
balance-sheet
3.74
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
balance-sheet
3.12
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GSK VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GSK | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 88.57% | -47.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 11.47% | -1.57 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 16.4x | +4.55 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | 6.48% | -4.27 | UNH | /fcf-yield <GO> |
| Operating Margin | 13.90% | 4.82% | +9.08 | GSK | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 3.14% | +7.76 | GSK | /net-margins <GO> |
| Revenue Growth (YoY) | 8.80% | 6.46% | +2.34 | GSK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.74 | 3.12 | +0.62 | GSK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | GSK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.74% | -0.04 | GSK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.2 | 56.0 | -4.82 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.33 | +0.62 | GSK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.5x | 17.1x | +13.41 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $98.47B | $364.66B | -$266.19B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GSK REV | UNH REV | GSK GROSS % | UNH GROSS % | GSK FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $447.57B | — | 88.7% | — | $16.07B |
| FY 2024 | — | $400.28B | — | 88.3% | — | $20.70B |
| FY 2023 | — | $371.62B | — | 89.6% | — | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GSK // BETA 0.95
UNH // BETA 0.33